Publications by authors named "Takuma Bando"

Claim this Profile
D
Durations of fever and other symptoms among COVID-19 outpatients administered ensitrelvir during the 2023 Japanese XBB epidemic period.
Naoki Kawai, Takuma Bando, Takeyuki Goto, Shinro Matsuura, Shin Nagao

J Infect Chemother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influenza vaccine effectiveness over 17 seasons in a large Japanese cohort: Analyses by age, virus type, underlying diseases and seasons before the COVID-19 pandemic.
Naoki Kawai, Hideyuki Ikematsu, Takuma Bando, Takashi Kawashima, Shinro Matsuura

J Infect Public Health· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effectiveness of repeated vaccination for COVID-19 symptom resolution during the KP.3-dominant epidemic period in Japan: A retrospective multicenter study.
Takuma Bando, Hideyuki Ikematsu, Naoki Kawai, Keigo Shibao, Masayuki Mizuguchi

J Infect Chemother· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season.
Naoki Kawai, Hideyuki Ikematsu, Takuma Bando, Woon Joo Lee, Shinro Matsuura

J Infect Chemother· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro neuraminidase inhibitory concentrations (IC) of four neuraminidase inhibitors in the Japanese 2023-24 season: Comparison with the 2010-11 to 2022-23 seasons.
Takeyuki Goto, Naoki Kawai, Takuma Bando, Tomonori Sato, Naoki Tani

J Infect Chemother· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023-2024 Season.
Takeyuki Goto, Naoki Kawai, Takuma Bando, Yoshio Takasaki, Shizuo Shindo

Influenza Other Respir Viruses· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season.
Takeyuki Goto, Naoki Kawai, Takuma Bando, Yoshio Takasaki, Shizuo Shindo

Antiviral Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro neuraminidase inhibitory concentrations (IC) of four neuraminidase inhibitors in the Japanese 2022-23 season: Comparison with the 2010-11 to 2019-20 seasons.
Takeyuki Goto, Naoki Kawai, Takuma Bando, Naoki Tani, Yong Chong

J Infect Chemother· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate: A study of the 2017/18 and 2018/19 seasons and comparison with the 2011/12 to 2016/17 Japanese influenza seasons.
Naoki Tani, Naoki Kawai, Hideyuki Ikematsu, Takuma Bando, Norio Iwaki

J Infect Chemother· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility of epidemic viruses to neuraminidase inhibitors and treatment-emergent resistance in the Japanese 2019-20 influenza season.
Naoki Tani, Naoki Kawai, Yong Chong, Takuma Bando, Norio Iwaki

J Infect· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of respiratory symptoms and health-related quality of life with peramivir in influenza patients with chronic respiratory disease: Additional outcomes of a randomized, open-label study.
Motokazu Kato, Yutaka Saisho, Hiroshi Tanaka, Takuma Bando

Influenza Other Respir Viruses· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
Yong Chong, Naoki Kawai, Naoki Tani, Takuma Bando, Yoshio Takasaki

Antiviral Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre-existing chronic respiratory disease: Findings of a randomized, open-label study.
Motokazu Kato, Yutaka Saisho, Hiroshi Tanaka, Takuma Bando

Influenza Other Respir Viruses· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro neuraminidase inhibitory concentration (IC) of four neuraminidase inhibitors in the Japanese 2018-19 season: Comparison with the 2010-11 to 2017-18 seasons.
Hideyuki Ikematsu, Naoki Kawai, Naoki Tani, Yong Chong, Takuma Bando

J Infect Chemother· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of fever and PA/I38X-substituted virus emergence in patients treated with baloxavir in the 2018-2019 influenza season.
Hideyuki Ikematsu, Naoki Kawai, Naoki Tani, Yong Chong, Norio Iwaki, Takuma Bando

J Infect Chemother· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro neuraminidase inhibitory concentration (IC) of four neuraminidase inhibitors in the Japanese 2017-18 season: Comparison with the 2010-11 to 2016-17 seasons.
Hideyuki Ikematsu, Naoki Kawai, Yong Chong, Takuma Bando, Norio Iwaki

J Infect Chemother· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis